Sector Snap: Handsets decline on Apple forecast - Boston Globe
NEW YORK A disappointing forecast from iPhone maker Apple Inc. dragged shares of other handset makers lower Monday, even as a weak quarterly report from Texas Instruments Inc. weighed on the broader technology sector. Apple's shares tumbled $13.35

James Levine health update: Malignant tumor removed from kidney - St. Louis Post-Dispatch
James Levine, music director of the Metropolitan Opera and the Boston Symphony Orchestra, had to bow out of his summer duties at the Tanglewood Festival in order to have a kidney removed. The originally reported cause of the removal was a cyst

Roche Bids to Buy Genentech Shares for $43.7 Billion (Update3) - Bloomberg
July 21 (Bloomberg) — Roche Holding AG , the world's biggest maker of cancer drugs, offered to buy the rest of Genentech Inc. for $43.7 billion to increase its share of profit from the best-selling Avastin and Herceptin tumor medicines. Genentech

Connexin-43 upregulation in micrometastases and tumor vasculature and - BioMed Central
The modulation of gap junctional communication between tumor cells and between tumor and vascular endothelial cells during tumorigenesis and metastasis is complex. The notion of a role for loss of gap junctional intercellular communication in

Magnets Capture Cancer Cells - ABC News
Magnetic nanoparticles coated with a specialized targeting molecule were able to latch on to cancer cells in mice and drag them out of the body. The results are described in a study published online this month in the Journal of the American Chemical

Jennerex Publishes Clinical Trial Data With Lead Product JX-594 - Forbes
SAN FRANCISCO, and YONGIN-SI, South Korea, July 22 /PRNewswire/ — Jennerex, Inc. (San Francisco, CA and Ottawa, Ontario), and its South Korean partner Green Cross Corp., announced today that novel findings from a Phase I clinical trial of its first